United Kingdom· GB-APID-45864511000001103
Ziihera 300mg powder for concentrate for solution for infusion vials
A zanidatamab product containing zanidatamab, registered in United Kingdom by Jazz Pharmaceuticals UK Ltd. The same ATC class is registered in 10 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Zanidatamab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FD07 (zanidatamab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Zanidatamab · ATC L01FD07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Zanidatamab
- Manufacturer
- Jazz Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FD07
- ATC class
- Zanidatamab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin0368727009943
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zanidatamab in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZIIHERAJazz Pharmaceuticals Ireland Ltd, Dublin
- FinlandZiiheraJazz Pharmaceuticals Ireland Limited
- BelgiumZiihera 300 mgJazz Pharmaceuticals Ireland
- IcelandZiiheraJazz Pharmaceuticals Ireland Limited
- PolandZiiheraJazz Pharmaceuticals Ireland Ltd
- SwedenZiihera 300 mg Pulver till koncentrat till infusionsvätska, lösningJazz Pharmaceuticals Ireland Limited
- IrelandZiihera 300 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Ireland Limited
- United StatesZIIHERAJazz Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ziihera
- Liechtenstein · Ziihera
- Norway · Ziihera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ba692fb-b4f9-4c10-872e-42529e5bd3fb GET /v1/drugs/0ba692fb-b4f9-4c10-872e-42529e5bd3fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45864511000001103",
"desc": "Ziihera 300mg powder for concentrate for solution for infusion vials (Jazz Pharmaceuticals UK Ltd)",
"form": "Powder for solution for infusion",
"vpid": "45874311000001100",
"source": "dmd",
"vtm_id": "45873011000001100",
"strength": "300 mg",
"substance": "Zanidatamab",
"ingredient": "Zanidatamab",
"supplier_code": "34938211000001101"
}See everything about zanidatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.